List view / Grid view
The N439K mutation improves the interaction between SARS-CoV-2 Spike protein and the viral receptor ACE2 and eludes antibody-mediated immunity, say investigators.
Research suggests heparin could be repurposed for COVID-19 because it can bind to the SARS-CoV-2 Spike protein and prevent the virus from infecting cells in vitro.
Researchers have suggested using melatonin in a nasal spray to create a protective barrier against SARS-CoV-2 in pre-symptomatic patients.
The lead candidate, ADG2, was able to neutralise SARS-CoV and various strains of SARS-CoV-2, including those that are resistant to currently available antibody treatments.
In murine models of COVID-19, researchers found that non-steroidal anti-inflammatory drugs (NSAIDs) can suppress the inflammatory response and production of antibodies.
By combining nanobodies targeting different regions of the SARS-CoV-2 Spike protein, researchers were able to protect cells from infection.
Researchers will use the in vitro model to study how respiratory viruses, like SARS-CoV-2, cause Acute Respiratory Distress Syndrome (ARDS) and develop potential interventions.
Computational drug screening has shown that chemotherapy drug pralatrexate could potentially be repurposed to treat COVID-19.
Opaganib reduced blood clot length and weight in a pre-clinical model of Acute Respiratory Distress Syndrome (ARDS).
The study found five key genetic differences when they compared sequences from severe COVID-19 patients to healthy individuals.
A team has found that their drug Molnupiravir (MK-4482/EIDD-2801) acts as an antiviral against SARS-CoV-2 in pre-clinical studies.
Researchers show that neutralising antibodies targeting the SARS-CoV-2 Spike protein have four distinct structures.
The new study shows how SARS-CoV-2 significantly remodels cellular processes in just an hour and identifies potential drug targets and therapeutics for COVID-19.
Researchers report that their LEAPS COV-19 peptides significantly improved survival in a murine model of COVID-19.
Rodent studies show that using antibodies with different targets and modes of action in combination is more effective at preventing and treating COVID-19.
